Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global Adderall drug market size is being driven by the rising prevalence of ADHD, which was close to USD 20.90 billion in 2023. The market is expected to grow with a CAGR of 4% during the forecast period of 2024-2032. The market is expected to reach a value of about USD 29.75 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Adderall is a trade name of the drug amphetamine. It is an FDA-approved prescription drug and first choice treatment option for attention deficit hyperactivity disorder (ADHD). It is also used for the treatment of narcolepsy, a chronic sleep disorder that is characterised by extreme daytime sleepiness and unexpected sleep episodes.
ADHD is a heterogeneous neurodevelopmental syndrome that comprises hyperactivity, increased impulsivity, and developmentally inappropriate inattentiveness. Multiple aspects of life are greatly hampered by ADHD, which can result in underachievement in school, unemployment, a failed marriage, and criminal activity, among other things.
Additionally, several comorbid mental problems, such as antisocial personality disorder, self-harm, and substance abuse, exhibit substantial correlations with ADHD, inflict significant burden on families and society.
Usage of Adderall for a prolonged period may lead to dependency or misuse of the drug and resultant adverse cardiovascular events. The effectiveness of Adderall in long-term use has not been evaluated in clinical trials thoroughly, therefore, when prescribed, it is necessary to re-evaluate the efficacy of the drug periodically by physicians.
Contraindications of Adderall are arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, hypersensitivity (idiosyncrasy to sympathomimetics amines, and glaucoma.
Some serious side effects include slow growth in children, seizures, blurred vision, or change in eyesight whereas some common side effects of this drug consist of headache, stomachache, trouble sleeping, decreased appetite, nervousness, and dizziness, among others.
The market is further divided into the following segmentations:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Disease Treatment
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising demand of Adderall drug market can be attributed to telehealth prescriptions of controlled substances like Adderall and Ritalin by online mental health care startups that were established during the pandemic and were permitted to do so by the US Drug Enforcement Agency.
Globally, ADHD is estimated to be affecting about 5% of children and teenagers. Due to the lack of standardised diagnostic criteria, adult ADHD appears to be overlooked in epidemiology. One of the most commonly given stimulants, along with Adderall are Ritalin and Concerta.
Cognitive and memory enhancer medications, supplements, and other substances are claimed to boost cognitive function in healthy persons, notably executive functions, attention, memory, creativity, or motivation. These medications comprise a variety of compounds that can boost cognitive performance and can increase or retain memory, stimulate learning, or prevent cognitive decline or dementia.
ADHD diagnosis can differ on the basis of age group and gender. Based on age group, the average age of ADHD diagnosis in children in the United States is about seven years, there is an increase of about two times in the cases of ADHD over the past ten years. The first signs and symptoms of ADHD are typically expected to appear between the age group of 3-6 years.
About 4% of adult Americans are dealing with ADHD symptoms on daily basis. Based on gender, the male population is about 3 times more likely to be diagnosed with ADHD than the female population.
The market is also rising with the rapid increase in the senior population, which is more vulnerable to neurological illnesses, such as Alzheimer's. Increased usage of cognitive medicines due to benefits, such as improved physical and mental performance, drives the market growth further. However, ethical concerns about the use of such pharmaceuticals can limit the market growth.
ADHD is treated with short, intermediate, and long-acting forms of stimulants. Adderall, being a short-acting stimulant, is usually consumed 2-3 times a day and has better control when it is in the system but it is difficult to keep the dose intake persistent on daily basis.
Amphetamine is a medication that is used to manage and treat ADHD and narcolepsy. It is classified as a stimulant of the central nervous system. Amphetamine has been shown to increase the concentrations of noradrenaline in the prefrontal cortex and dopamine in the striatum in a dose and time-dependent manner. The indistinct release of neurotransmitters such as adrenaline is known to have cardiovascular side effects.
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Disease Type |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of USD 20.90 billion in 2023.
The Adderall market is likely to be driven by the rising prevalence rate of ADHD, which is projected to grow at a CAGR of 4% between 2024 and 2032.
The primary driver driving market expansion is an increase in the senior population, which is predisposed to neurological illnesses such as ADHD.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
Adderall is a Schedule II prohibited drug; a prescription is required to buy it.
Body tends to tolerate Adderall and become less effective over time. Medical practitioners are expected to check the efficacy of the drug and range the doses accordingly.
The major players in the industry are Intas Pharmaceuticals, Aztiq Pharma Partners, Ascent Pharms, Inc., Aurolife Pharma LLC, Cediprof, Inc., Elite Labs, Inc., PuraCap Pharmaceutical, Granules Pharmaceutical, Inc., Nuvo Pharm, Shire LLC (Takeda Pharmaceutical Company Limited), Rhodes Pharma, Zydus Lifesciences Limited, and Teva Pharmaceutical, among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share